For the study, published June 13 in Science Translational Medicine, researchers used a highly virulent cholera strain taken from the Haiti outbreak to make the live vaccine, which they named HaitiV. During animal testing, researchers discovered the vaccine colonized in the small intestine just as quickly as the original cholera pathogen, thereby serving as a near-immediate probiotic against the virus.
Robert Hall PhD, a microbiologist at the National Institute of Allergy and Infectious Diseases, said this vaccine could reduce the need for antibiotic treatment and therefore lower the risk of causing increased antibiotic resistance in cholera.
Researchers believe the study’s findings could lead to other ways of treating bacterial diseases such as Escherichia coli and Clostridium difficle without antibiotics.
More articles on clinical leadership and infection control:
3 New York hospitals report higher than average SSI rates
UPMC physician: Providers need a ‘bolder’ approach to win the battle against sepsis
J&J Institute launches VR training program for surgeons, nurses
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
